The estimated Net Worth of Sean Bohen is at least $3.61 Milion dollars as of 20 November 2023. Dr Bohen owns over 57,225 units of Olema Pharmaceuticals stock worth over $1,788,375 and over the last 4 years he sold OLMA stock worth over $824,040. In addition, he makes $999,300 as Pres a CEO & Director at Olema Pharmaceuticals.
Sign up
Dr D OLMA stock SEC Form 4 insiders trading
Dr has made over 6 trades of the Olema Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 57,225 units of OLMA stock worth $824,040 on 20 November 2023.
The largest trade he's ever made was selling 57,225 units of Olema Pharmaceuticals stock on 20 November 2023 worth over $824,040. On average, Dr trades about 10,807 units every 105 days since 2020. As of 20 November 2023 he still owns at least 144,925 units of Olema Pharmaceuticals stock.
You can see the complete history of Dr Bohen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Sean P. Bohen M.D., Ph.D. biography
Dr. Sean P. Bohen M.D., Ph.D. is the Pres, CEO & Director at Olema Pharmaceuticals.
What is the salary of Dr D?
As the Pres a CEO & Director of Olema Pharmaceuticals, the total compensation of Dr D at Olema Pharmaceuticals is $999,300. There are no executives at Olema Pharmaceuticals getting paid more.
How old is Dr D?
Dr D is 54, he's been the Pres a CEO & Director of Olema Pharmaceuticals since . There are 2 older and 5 younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals, Inc. is Dr. Peter J. Kushner Ph.D., 82, who is the Chief Scientific Officer.
What's Dr D's mailing address?
Sean's mailing address filed with the SEC is C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO, CA, 94103.
Insiders trading at Olema Pharmaceuticals
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham a Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
What does Olema Pharmaceuticals do?
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
What does Olema Pharmaceuticals's logo look like?
Complete history of Dr Bohen stock trades at Olema Pharmaceuticals
Olema Pharmaceuticals executives and stock owners
Olema Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. Sean P. Bohen M.D., Ph.D.,
Pres, CEO & Director -
Dr. Cyrus L. Harmon Ph.D.,
CTO & Director -
Dr. Sean P. Bohen,
Pres, CEO & Director -
John B. Moriarty Jr.,
Exec. VP, Chief Legal Officer & Corp. Sec. -
Dr. Peter J. Kushner Ph.D.,
Chief Scientific Officer -
Dr. Naseem Zojwalla M.D.,
Chief Medical Officer -
Demiana Faltaos Ph.D., Pharm.D.,
VP & Head of Clinical Pharmacology -
Dr. Leslie Hodges Gallagher Ph.D.,
Sr. VP of Discovery Biology -
Kinney Horn,
Chief Bus. Officer -
Dr. David C. Myles,
Chief Devel. Officer -
Julie Dexter,
VP & Head of People -
Eva Stroynowski,
VP of Communications & Investor Relations -
Shane William Charles Kovacs M.B.A.,
Chief Operating & Financial Officer -
J. Scott Garland,
-
Frank Mccormick,
Director -
Andrew Rappaport,
-
Biomedical Innovation Maste...,
10% owner -
Asset Management, Lp Chen B...,
-
Partners L P/Ilbiotechnolog...,
-
Ian T Clark,
-
Gorjan Hrustanovic,
-
Sean Bohen,
PRESIDENT AND CEO -
Cynthia M Butitta,
-
David C. Myles,
CH. DISCOV. & NON-CLIN DEV OFF -
Yi Larson,
-
Peter J. Kushner,
CHIEF SCIENTIFIC OFFICER -
Shane William Charles Kovacs,
CH. OPERATING & FINANCIAL OFF. -
Kinney Horn,
Chief Business Officer -
Cyrus Harmon,
-
John B Moriarty,
EVP, Ch. Legal Officer & Sec. -
Biocapital Advisors Lp Para...,
-
G. Walmsley Graham,
-
Naseem Zojwalla,
CHIEF MEDICAL OFFICER